For the first time, there’s a flu shot specifically created for people over the age of 50 after the FDA approved Moderna’s mFLUSIVA, the first influenza vaccine to use mRNA technology. In clinical trials, mFLUSIVA was about 26.6% more effective at preventing laboratory-confirmed influenza illness than a traditional flu vaccine, according to the Bloomberg School of Public Health. It also produced a stronger immune response than traditional vaccin…